» Articles » PMID: 28393317

Impact of an Electronic Monitoring Device and Behavioral Feedback on Adherence to Multiple Sclerosis Therapies in Youth: Results of a Randomized Trial

Abstract

Purpose: To report the results of a randomized controlled trial using an electronic monitoring device (EM) plus a motivational interviewing (MI) intervention to enhance adherence to disease-modifying therapies (DMT) in pediatric MS.

Methods: Fifty-two youth with MS (16.03 ± 2.2 years) were randomized to receive either MI (n = 25) (target intervention) or a MS medication video (n = 27) (attention control). Primary endpoint was change in adherence. Secondary outcomes included changes in quality of life, well-being and self-efficacy. Random effects modeling and Cohen's effect size computation evaluated intervention impact.

Results: Longitudinal random effect models revealed that the MI group decreased their EM adherence (GroupxTime interaction = -0.19), while increasing frequency of parental DMT reminder (26.01)/administration (11.69). We found decreased EM use in the MI group at 6 months (Cohen's d = -0.61), but increased pharmacy refill adherence (d = 0.23). Parental reminders about medication increased in MI subjects vs controls (d = 0.59 at 3 months; d = 0.70 at 6 months). We found increases in self-reported adherence (d = 0.21) at 3 but not 6 months, fewer barriers to adherence at three (d = -0.58) and six months (d = -0.31), better physical (d = 0.23 at 3 months; d = 0.45 at 6 months), emotional (d = 0.25 at 3 months) and self-efficacy function (d = 0.55 at 3 months; 0.48 at 6 months), but worse well-being, including self-acceptance (d = -0.53 at 6 months) and environmental mastery (d = -0.42 at 3 and 6 months) in intervention as compared to control patients.

Conclusions: Participants receiving MI + EM experienced worsening on objective measures of adherence and increased parental involvement, but improved on some self- and parent-reported measures. MI participants reported improvements in quality of life and self-efficacy, but worsened well-being.

Citing Articles

Optimizing Drug Selection in Children with Multiple Sclerosis: What Do We Know and What Remains Unanswered?.

Suntornlohanakul R, Yeh E Paediatr Drugs. 2024; 27(2):161-179.

PMID: 39724509 DOI: 10.1007/s40272-024-00675-1.


The State of the Art of Pediatric Multiple Sclerosis.

Teleanu R, Niculescu A, Vladacenco O, Roza E, Perjoc R, Teleanu D Int J Mol Sci. 2023; 24(9).

PMID: 37175954 PMC: 10179691. DOI: 10.3390/ijms24098251.


The Economic and Humanistic Burden of Pediatric-Onset Multiple Sclerosis.

Greene N, Araujo L, Campos C, Dalglish H, Gibbs S, Yermilov I J Health Econ Outcomes Res. 2022; 9(2):103-114.

PMID: 36348724 PMC: 9584745. DOI: 10.36469/001c.37992.


Effect of electronic adherence monitoring on adherence and outcomes in chronic conditions: A systematic review and meta-analysis.

Chan A, Foot H, Pearce C, Horne R, Foster J, Harrison J PLoS One. 2022; 17(3):e0265715.

PMID: 35312704 PMC: 8936478. DOI: 10.1371/journal.pone.0265715.


Quality of Life of Children and Adolescents with Multiple Sclerosis-A Literature Review of the Quantitative Evidence.

Mroskova S, Klimova E, Majernikova L, Tkacova L Int J Environ Res Public Health. 2021; 18(16).

PMID: 34444393 PMC: 8392317. DOI: 10.3390/ijerph18168645.


References
1.
Jozefiak T, Larsson B, Wichstrom L, Mattejat F, Ravens-Sieberer U . Quality of Life as reported by school children and their parents: a cross-sectional survey. Health Qual Life Outcomes. 2008; 6:34. PMC: 2409303. DOI: 10.1186/1477-7525-6-34. View

2.
Varni J, Seid M, Kurtin P . PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001; 39(8):800-12. DOI: 10.1097/00005650-200108000-00006. View

3.
Graves M, Roberts M, Rapoff M, Boyer A . The efficacy of adherence interventions for chronically ill children: a meta-analytic review. J Pediatr Psychol. 2009; 35(4):368-82. DOI: 10.1093/jpepsy/jsp072. View

4.
Thannhauser J, Mah J, Metz L . Adherence of adolescents to multiple sclerosis disease-modifying therapy. Pediatr Neurol. 2009; 41(2):119-23. DOI: 10.1016/j.pediatrneurol.2009.03.004. View

5.
McKay K, Tremlett H, Patten S, Fisk J, Evans C, Fiest K . Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. Mult Scler. 2016; 23(4):588-596. PMC: 5407504. DOI: 10.1177/1352458516657440. View